Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks
BackgroundThis study examines the risks of hypertension and thrombotic events in NSCLC patients treated with Tyrosine Kinase Inhibitors (TKIs).ObjectiveTo compare the safety profiles of TKIs used in NSCLC treatment, focusing on hypertension and thrombotic risks.MethodsA comprehensive search identifi...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1491990/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582924796428288 |
|---|---|
| author | Mingming Tan Chenwei Pu Zhenzhen Wang Chengwei Jin |
| author_facet | Mingming Tan Chenwei Pu Zhenzhen Wang Chengwei Jin |
| author_sort | Mingming Tan |
| collection | DOAJ |
| description | BackgroundThis study examines the risks of hypertension and thrombotic events in NSCLC patients treated with Tyrosine Kinase Inhibitors (TKIs).ObjectiveTo compare the safety profiles of TKIs used in NSCLC treatment, focusing on hypertension and thrombotic risks.MethodsA comprehensive search identified randomized controlled trials evaluating the effects of TKIs in NSCLC patients. Bayesian network meta-analysis was employed to construct a comparative network of treatments.ResultsThirty studies involving 11,375 patients were included. Erlotinib had the lowest incidence of hypertension (SUCRA: 91.1%), followed by chemotherapy (88.8%). For thrombotic events, Erlotinib had the lowest risk (SUCRA: 66.1%), while Anlotinib and Cabozantinib had the highest thrombotic risks (SUCRA: 26.9%).ConclusionErlotinib presents the lowest risk for hypertension and thrombotic events, making it a preferred choice for NSCLC patients with cardiovascular concerns.Systematic review registrationhttps://www.crd.york.ac.uk/prospero, identifier CRD42024530770. |
| format | Article |
| id | doaj-art-0aa392ce4d0a47b5a50c36222fe5dc41 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-0aa392ce4d0a47b5a50c36222fe5dc412025-01-29T06:45:40ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011610.3389/fphar.2025.14919901491990Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risksMingming Tan0Chenwei Pu1Zhenzhen Wang2Chengwei Jin3Department of Respiratory and Critical Care Medicine, Zibo Central Hospital, Zibo, ChinaDepartment of Respiratory and Critical Care Medicine, Zibo Central Hospital, Zibo, ChinaDepartment of Infectious Diseases, Zibo Central Hospital, Zibo, ChinaDepartment of Cardiology, Zibo Central Hospital, Zibo, ChinaBackgroundThis study examines the risks of hypertension and thrombotic events in NSCLC patients treated with Tyrosine Kinase Inhibitors (TKIs).ObjectiveTo compare the safety profiles of TKIs used in NSCLC treatment, focusing on hypertension and thrombotic risks.MethodsA comprehensive search identified randomized controlled trials evaluating the effects of TKIs in NSCLC patients. Bayesian network meta-analysis was employed to construct a comparative network of treatments.ResultsThirty studies involving 11,375 patients were included. Erlotinib had the lowest incidence of hypertension (SUCRA: 91.1%), followed by chemotherapy (88.8%). For thrombotic events, Erlotinib had the lowest risk (SUCRA: 66.1%), while Anlotinib and Cabozantinib had the highest thrombotic risks (SUCRA: 26.9%).ConclusionErlotinib presents the lowest risk for hypertension and thrombotic events, making it a preferred choice for NSCLC patients with cardiovascular concerns.Systematic review registrationhttps://www.crd.york.ac.uk/prospero, identifier CRD42024530770.https://www.frontiersin.org/articles/10.3389/fphar.2025.1491990/fullnon-small cell lung cancertyrosine kinase inhibitorshypertensionthrombotic eventsnetwork meta-analysisNSCLC |
| spellingShingle | Mingming Tan Chenwei Pu Zhenzhen Wang Chengwei Jin Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks Frontiers in Pharmacology non-small cell lung cancer tyrosine kinase inhibitors hypertension thrombotic events network meta-analysis NSCLC |
| title | Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks |
| title_full | Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks |
| title_fullStr | Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks |
| title_full_unstemmed | Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks |
| title_short | Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks |
| title_sort | comparative safety profile of tyrosine kinase inhibitors in nsclc a network meta analysis of hypertension and thrombotic risks |
| topic | non-small cell lung cancer tyrosine kinase inhibitors hypertension thrombotic events network meta-analysis NSCLC |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1491990/full |
| work_keys_str_mv | AT mingmingtan comparativesafetyprofileoftyrosinekinaseinhibitorsinnsclcanetworkmetaanalysisofhypertensionandthromboticrisks AT chenweipu comparativesafetyprofileoftyrosinekinaseinhibitorsinnsclcanetworkmetaanalysisofhypertensionandthromboticrisks AT zhenzhenwang comparativesafetyprofileoftyrosinekinaseinhibitorsinnsclcanetworkmetaanalysisofhypertensionandthromboticrisks AT chengweijin comparativesafetyprofileoftyrosinekinaseinhibitorsinnsclcanetworkmetaanalysisofhypertensionandthromboticrisks |